跳至主要内容
临床试验/PER-079-05
PER-079-05已完成未知

PREDICTION OF RESPONSE AND TOXICITY IN PATIENTS WHO RECEIVE CHEMOTHERAPY FOR BREAST CANCER, CORRELATIVE STUDY OF GENOMICS, PROTEOMICS AND PHARMACOGENOMY

HOSSIER ONCOLOGY GROUP,0 个研究点目标入组 0 人开始时间: 2006年2月8日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
0 至 0(—)

入选标准

  • 1. Histological and cytologic confirmation of locally advanced or metastatic breast adenocarcinoma.
  • 2. Disease susceptible to pre-treatment core or incisional biopsy with adequate tissue sample for histology, and genomics / proteomics analysis.
  • 3. Measurable and evaluated disease, between the 21 days prior to the start of the treatment protocol, using the RECIST criteria
  • 4. Planning of chemotherapy with any of the study regimens.
  • 5. Appropriate performance status and organic function.
  • 6. Informed consent and authorization exempting the use of the
  • personal health information.
  • 7. Absence of other uncontrolled or surgical medical conditions that the investigator considers may compromise participation in the study.
  • 8. Woman over 18 years old.

排除标准

  • 1. Any other uncontrolled medical or surgical condition that may compromise your participation in the study.
  • 2. Pregnancy. A negative pregnancy test must be obtained between the 7 days prior to registration for treatment of the protocol in women of childbearing age.
  • 3. Refusal to have adequate contraception control.
  • 4. Breastfeeding.

研究者

发起方
HOSSIER ONCOLOGY GROUP,

相似试验

PREDICTION OF RESPONSE AND TOXICITY IN PATIENTS WHO... | 临床试验